WAM
AKTX

Warberg Asset Management’s Akari Therapeutics AKTX Stock Holding History

Warberg Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,709
Closed -$88.7K – 194
2025
Q4 		$88.7K Buy
+7,709
New +$179K 0.01% 141

Other funds holding AKTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $673M AUM 55.24% 1-Year Est. Return

Warberg Asset Management's AKTX Position: Q1 2026 in Review

Warberg Asset Management sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 7,709 shares — an estimated $88.7K sold.

Warberg Asset Management first reported a position in AKTX in Q4 2025 and held it in 1 quarter. The position peaked at $88.7K in Q4 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Warberg Asset Management reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Warberg Asset Management sold 7,709 Akari Therapeutics shares in Q1 2026, an estimated $88.7K.
  • Warberg Asset Management first reported a position in Akari Therapeutics in Q4 2025 and held it in 1 quarter.
  • Warberg Asset Management's Akari Therapeutics position peaked at $88.7K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Warberg Asset Management's 13F filing for Q1 2026, filed 7 May 2026.